Mucomax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucomax

Property Description
Active Ingredient Acetylcysteine (N-acetyl-L-cysteine, NAC)
Form Oral Solution, Effervescent Tablets, Solution for Injection/Inhalation
Pharmacological Class Mucolytic Agent, Secretolytic Drug, Detoxifying Agent
Common Use Reducing the viscosity of respiratory secretions
Origin Synthetic compound

Mucomax is a trade name for a therapeutic compound that utilizes the active ingredient Acetylcysteine, a versatile substance that is clinically recognized and pharmacologically supported for its functions as both a mucolytic agent and a detoxifying agent. It is designed to manage conditions involving thick, excess biological fluids, specifically viscous respiratory secretions.


Mucomax: Identity, Origin, and Pharmacological Classification

Mucomax is a single-ingredient medicine containing Acetylcysteine (chemically N-acetyl-L-cysteine, or NAC), which is classified as a synthetic compound derived from the naturally occurring amino acid, L-cysteine. As a secretolytic drug, its primary function places it within the mucolytic agent pharmacological class, meaning it works to modify the physical characteristics of biological secretions. Its pharmacological role includes thinning mucus, an action that facilitates the clearing of airways. The unique thiol group in its structure gives it a crucial secondary role as a specific detoxifying agent. This capacity to restore the antioxidant glutathione is critical in managing certain systemic toxic exposures.


Pharmaceutical Forms and Intended Administration Routes

The Acetylcysteine component of Mucomax is prepared across several modalities, including effervescent tablets or oral solution and specialized sterile solution for inhalation or solution for injection. This range of preparations defines the intended route of administration, which can be inhalational for direct respiratory action, oral, or parenteral (intravenous) for rapid, systemic action. The availability of these distinct forms allows the drug to address general mucus clearance and also serve its emergency antidote function.

What side effects are possible with Mucomax?

Mucomax: Possible Side Effects and Safety Information

Adverse reactions associated with Mucomax (Acetylcysteine) are formally documented and categorized by frequency and the body system affected (System Organ Class).

Frequency-Classified Adverse Reactions

Side effects are classified according to their reported incidence from clinical trials and post-marketing experience:

  • Uncommon (affects 1 to 10 users in 1,000): Hypersensitivity, headache, tinnitus, tachycardia, vomiting, diarrhea, stomatitis, abdominal pain, nausea, urticaria, rash, angioedema, pruritus, pyrexia, hypotension.
  • Rare (affects 1 to 10 users in 10,000): Anaphylactic reaction (up to shock), dyspnea, bronchospasm (mainly in patients with bronchial asthma), dyspepsia.
  • Very Rare (affects less than 1 user in 10,000): Haemorrhage, anaphylactic shock, severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome and toxic epidermal necrolysis, face oedema.
  • Not Known (cannot be estimated from the available data): Platelet aggregation decreased, anaemia.

Serious Safety Considerations

Regulatory authorities specifically highlight the potential for Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome and toxic epidermal necrolysis, and Anaphylactic Reactions, which are rare but severe hypersensitivity events. These reactions are considered clinically significant and may involve the skin, immune system, and respiratory system. Hypersensitivity to the active substance or any excipients is a contraindication documented in the official safety information.

Population-Specific Notes

Particular caution and monitoring are advised for patients with bronchial asthma due to the reported risk of bronchospasm. The risk profile emphasizes that in the event of any signs of hypersensitivity, the drug should be stopped immediately.

Overdose and Emergency Response

Overdose and When to Seek Help

Mucomax (N-acetylcysteine) is an established treatment for preventing or lessening liver damage following an overdose of acetaminophen (paracetamol). Official regulatory profiles of acetaminophen overdose are structured around the primary risk of severe hepatic injury (liver failure), which can be fatal. This injury may follow the ingestion of a potentially hepatotoxic quantity of acetaminophen, such as 150 mg/kg or greater in an acute ingestion, or repeated supratherapeutic ingestions.


Clinical Manifestations and Urgency

The initial presentation of an acetaminophen overdose can be asymptomatic or involve non-specific symptoms such as nausea, vomiting, dizziness, or headache. Crucially, the absence of severe symptoms does not rule out progressive, severe liver damage (hepatocellular necrosis).

Immediate medical help must be sought if a potentially toxic quantity of acetaminophen is suspected. The effectiveness of N-acetylcysteine in preventing severe, irreversible hepatic injury is time-dependent, with a critical window for maximal protection occurring between 0 and 8 hours after ingestion. Treatment must be initiated as soon as possible regardless of the patient's current symptoms to maximize the chance of preventing life-threatening liver failure.

Therapeutic Uses of Mucomax

The medication may be part of symptomatic management across two distinct domains: assisting with the handling of distressing symptoms and supporting the patient during specific acute toxicological events.

In clinical practice, this medicine helps address symptom clusters related to chest congestion when thick or abnormal mucus is present.

Symptomatic Relief for Viscous Respiratory Conditions

This medication is applied in addressing conditions where patients experience symptoms related to physical discomfort due to the inability to effectively clear abnormally viscid (thick) mucus. This is relevant for conditions presenting with acute episodes like Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and may be part of symptomatic management during phases of increased distress from pneumonia or severe bronchitis. By addressing the thick nature of the phlegm, this contributes to easing the overall symptom load related to physical discomfort and supports general well-being during symptomatic phases. It is relevant when supportive symptom management is appropriate.

“It is commonly used to help with symptoms related to physical discomfort caused by thick secretions in the airways.”

Emergency Intervention in Systemic Support

In a separate therapeutic context, the medication is commonly used in situations where additional symptomatic support is needed following a specific toxic exposure event, such as the ingestion of potentially hepatotoxic doses of Acetaminophen (Paracetamol). This application is relevant in clinical settings that involve acute or disruptive symptom patterns. It provides support that helps ease the overall symptom burden, and supports the patient during difficult episodes by easing distress, which helps improve day-to-day comfort during symptomatic periods.

Mini-Listing of Indications (Therapeutic Areas): The primary uses fall into managing symptoms of bronchopulmonary disorders such as COPD, cystic fibrosis, and bronchitis, and its specialized role in acute acetaminophen poisoning.

Quick Fact: Relief for Respiratory Congestion Quick Fact: Relief for Thick Mucus This medication may assist with managing symptoms related to chest congestion when thick secretions interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile: MUCOMYST (Acetylcysteine)

This eligibility information is based strictly on authoritative government regulatory documents from agencies such as the FDA and EMA for the active ingredient acetylcysteine.


Populations Who Cannot Use the Medicine (Contraindications)

Classification Rule
Known Sensitivity Use is contraindicated in patients with a known hypersensitivity or allergy to acetylcysteine or any of the product's excipients.

Populations Requiring Caution or Conditional Use

Classification Rule
Age Restriction The medicine must not be given to children under 2 years of age for mucolytic (mucus-thinning) purposes.
Pre-existing Conditions Caution and close monitoring are required for patients with bronchial asthma or a history of peptic ulcers (due to potential for bronchospasm or gastric irritation).
Pregnancy/Lactation Pregnancy Category B (FDA) and generally preferable to avoid (EMA). It is unknown if the drug passes into human milk, requiring caution in nursing women.

Eligibility Summary

Official labeling defines who must not use the medicine primarily through the strict contraindication of known sensitivity/allergy. Additional constraints involve the prohibition of mucolytic use in very young children and the need for medical caution when treating individuals with certain respiratory or gastrointestinal conditions. Use during pregnancy and breastfeeding is subject to caution due to limitations in available human safety data.

What should I know about interactions with other medicines?

Mucomax Interactions with other medicines and products

Interaction Scope

Official regulatory documents detail specific interaction patterns for the active substance. The mechanistic basis of these interactions includes pharmacodynamic potentiation that affects cardiovascular function and physiochemical/chemical effects. Nitroglycerin and antitussive drugs are explicitly listed as interacting medicines, alongside Oral Antibiotics and Activated Charcoal. This profile is characterized by restrictions on co-administration, timing-based rules, and population-specific warnings.

Timing and Exposure Constraints

A mandatory timing separation is required for certain medicines: Oral antibiotics (such as cephalosporins) must be administered at least two hours before or after Mucomax due to the risk of in vitro chemical inactivation. The physiochemical interaction with Activated Charcoal can reduce the absorption and effectiveness of oral Acetylcysteine. Official labeling also notes that drug clearance is lower in patients with severe liver injury or End-Stage Renal Disease, resulting in greater systemic exposure.

Interaction-Related Restrictions

  • Pharmacodynamic Restriction: Co-administration with antitussive drugs is restricted to prevent the build-up of bronchial secretions.
  • Hypotension Risk: Concurrent use with Nitroglycerin may result in significant hypotension due to additive vasodilatory effects. Caution is also advised with other antihypertensive medications.
  • Excipient Contraindication: Product forms containing aspartame are formally contraindicated in individuals with Phenylketonuria (PKU).

Laboratory Interference

The medicine is officially documented to interfere with specific laboratory tests, including colorimetric assays for Salicylates and certain tests for ketones in urine.

Connection to the overall interaction profile

The regulatory interaction profile for Mucomax is structured by pharmacodynamic potentiation that affects cardiovascular function, procedural constraints requiring administration timing separation, and population-specific notes detailing altered exposure in patients with impaired clearance.

Mechanism of Action

How Mucomax Works: Mechanism of Action

Direct Mucus Structure Breakdown (Mucolytic Action)

This mechanism involves the direct chemical action of the drug’s active molecule on mucin glycoproteins, where its free sulfhydryl ( -SH) group acts as a reductant to break the disulfide bonds ( S-S) that create mucus viscosity. This depolymerization leads to a profound reduction in mucus thickness and elasticity, facilitating the physiological process of secretion clearance from the airways.


Cellular Antioxidant and Redox Support

The drug acts as a precursor to the amino acid L-cysteine, the rate-limiting building block for the synthesis of the crucial cellular antioxidant, glutathione ( GSH). By replenishing GSH stores, and by acting as a direct scavenger of Reactive Oxygen Species ( ROS), the mechanism helps restore cellular redox balance. This action increases the cell’s capacity for detoxification of reactive species, which are implicated in localized cellular dysfunction.


Modulating Inflammatory Pathways

The reduction of oxidative stress, achieved through the antioxidant mechanism, modulates key signal transduction pathways involved in inflammation. This action helps inhibit the activation of the protein complex NF-kappa B, which governs the transcription and release of many pro-inflammatory mediators. This modulates pathway dynamics and reduces the synthesis of pro-inflammatory mediators, thereby attenuating the cellular signals that govern mucus hypersecretion and localized cellular response.

Dosage and Administration Information

How to Use Mucomax (Acetylcysteine)

Standard instructions for use are determined by the intended administration route and purpose. Dosage is often calculated precisely based on the patient's body weight.


Administration Routes and Dosage Forms

The medicine is supplied for several routes, each with specific preparation requirements:

Route of Administration Official Dosage Form Key Procedural Requirement
Intravenous (IV) Infusion Solution for Injection/Infusion Must be diluted with specific infusion fluids (e.g., 5% Dextrose) before administration.
Oral Solution, Tablet, or Granules Liquid forms must often be diluted before swallowing.
Inhalation Solution for Nebulisation Administered via a nebulizer.

Fixed-Time Dosing Regimens

For the treatment protocol related to paracetamol overdose, a multi-step regimen is mandatory:

  • IV Antidote Regimen: The total dose of 300 mg/kg body weight is delivered continuously over a 21-hour period. This is divided into three consecutive, timed infusions at specified rates (e.g., 150 mg/kg first dose, 50 mg/kg second dose, 100 mg/kg third dose).
  • Oral Antidote Regimen: This protocol involves a loading dose (140 mg/kg) followed by 17 maintenance doses (70 mg/kg each) given every 4 hours.

Preparation and Handling Specifics

When administering intravenously, specific equipment precautions are required: administration sets containing aluminium must not be used for preparation or infusion, as the medication may react with the metal. For the oral route, if a dose is vomited within one hour of administration, the dose must be re-administered to maintain the protocol's integrity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mucomax

Evidence for Mucolytic Use in Thick Respiratory Secretions

Research was studied for conditions characterized by thick mucus and is primarily based on short-term randomized controlled trials (RCTs) and systematic reviews. These studies explored how the medicine was associated with changes in the physical properties of sputum, such as viscosity. Reported outcomes concerning improvement in general clinical symptoms were mixed across the different short-term trials. Long-term effects are not fully established for this particular use; most available data is concentrated on follow-up durations of seven days or less.

Evidence for Intervention in Acute Acetaminophen Poisoning

In a separate context, Mucomax was studied for its role as an antidote following toxic ingestion of Acetaminophen (Paracetamol). This research is based on multicenter, single-arm clinical trials and systematic reviews tracking prevention of hepatotoxicity (severe liver damage) and mortality rate. The research describes that early treatment initiation (within eight to ten hours) was associated with prevention of liver damage in a large portion of the observed populations. This application has a high degree of consensus based on research examining temporary physiological imbalance in acute settings.

Studies on Chronic Use and Exacerbation Prevention in COPD

For patients with Chronic Obstructive Pulmonary Disease (COPD), research was evaluated in long-term, placebo-controlled randomized trials. These studies explored changes in the frequency of acute exacerbations and hospitalization rates over periods up to three years in duration. Findings describe patterns observed in the studies related to the frequency of acute exacerbations when compared to placebo. However, research highlights changes measured during the study period were mixed regarding other key outcomes reflecting daily functioning or activity level, such as lung function decline ( FEV1).

What is Still Uncertain About the Research

The research on Mucomax is characterized by several known limitations. Evidence quality varies across studies, particularly in the older mucolytic trials. For the use in COPD, research describes significant heterogeneity in the populations studied, meaning the results apply only to the populations studied and findings describe group patterns, not personal outcomes. There is limited information for long-term outcomes regarding long-term functional outcomes across the respiratory indications.

Frequently Asked Questions (FAQ)

Common questions about Mucomax (FAQ)


Q: Can Mucomax be taken with food, or does it need to be taken on an empty stomach?

Official instructions for the oral solution indicate that administration typically involves mixing the solution with a soft drink or juice to improve the taste. The regulatory documents do not provide an explicit requirement stating that the medicine must be taken specifically with or without a meal.


Q: Can children use Mucomax?

Official labeling prohibits the use of the medicine for mucus-thinning purposes in children under 2 years of age. For older children, use requires clinical supervision and is based on specific dosage guidelines.


Q: If I am pregnant or breastfeeding, is there official guidance on Mucomax use?

The medicine is classified as Pregnancy Category B by the FDA. The official guidance describes the drug as generally preferable to avoid during pregnancy and notes that it is unknown if the drug passes into human milk, requiring caution for nursing women.


Q: Does Mucomax interact with common cold and flu medications?

Regulatory documents describe a restriction on concurrent use with antitussive drugs (cough suppressants) to prevent the build-up of bronchial secretions. Additionally, the label notes known interactions with Oral Antibiotics and Activated Charcoal.


Q: Is it safe to drive while using Mucomax?

Official safety information reports side effects such as headache and drowsiness as potential effects. The presence of these potential reactions means that the ability to drive or operate machinery may be affected.


Q: Is Mucomax an antibiotic?

No, Mucomax is not classified as an antibiotic drug. According to regulatory bodies, it is classified as a mucolytic agent (a medicine that thins mucus) and a detoxifying agent (an antidote for certain types of poisoning).


Q: How quickly does Mucomax start working?

Following oral administration, the maximum concentration of the active substance in the blood is typically reached within one to three hours. However, the onset of the medicine's clinical effect can depend on the specific condition being treated.


Q: What are the most common reasons people are prescribed Mucomax?

The primary regulated uses of Mucomax are as a mucolytic agent to help reduce the viscosity of thick respiratory secretions, and as a detoxifying agent (antidote) for managing certain systemic toxic exposures.


Q: Is it common to feel tired when using Mucomax?

Official safety documents list unusual tiredness or weakness and malaise as reported adverse events. The frequency of these specific effects is generally uncommon or cannot be precisely estimated from the available regulatory data.


Q: Why are there different strengths of Mucomax available?

The active substance is made available in different strengths and concentrations to accommodate the varied needs of its administration routes, such as intravenous infusion versus inhalation. This allows the medicine to meet specific procedural requirements, including the high dosage needed for its antidote function.


Q: Is Mucomax generally considered safe for older adults?

Official regulatory documents note that the safety and effectiveness of the medicine in older adult patients have not been fully established. This is due to a lack of adequate or well-controlled studies specifically focused on this population.


Q: If Mucomax is used by someone who shouldn't use it, what happens?

The strictest restriction is for those with a known hypersensitivity or allergy to the active substance. Using the medicine when contraindicated for allergy carries the risk of severe allergic reactions, which can potentially involve anaphylactic shock and severe cutaneous adverse reactions (SCARs).


Q: Is it normal to have a slight headache after starting Mucomax?

Headache is documented in official safety information as an uncommon side effect. This means it is reported to affect 1 to 10 users out of every 1,000 users.


Q: Can Mucomax cause changes in mood or sleep?

Official regulatory documents list adverse events such as drowsiness (a sleep-related effect) and anxiety. However, the frequency of these particular effects is not known or cannot be estimated from the available data.


Q: Does using Mucomax affect the results of any common lab tests?

Yes, the medicine is formally documented to interfere with certain laboratory tests. This includes colorimetric assays used for salicylates and specific tests used to detect ketones in urine.


Q: Why is Mucomax sometimes prescribed for uses that aren't its main purpose?

The active component is chemically classified by regulatory bodies as both a mucolytic agent and a detoxifying agent. This unique dual function means it is regulated for distinct medical purposes, such as addressing thick mucus and serving as an antidote.


Q: Is Mucomax available over-the-counter in some regions?

In the United States, the medicine's active component is an FDA-approved prescription drug. Availability and classification (such as over-the-counter or prescription-only status) can vary significantly by region and country.


Q: Is Mucomax considered a controlled substance?

No, the medicine is not generally classified as a controlled substance under the US Controlled Substances Act.


Q: Do experts know exactly how Mucomax works in the body?

Official documents describe the mechanism as involving direct chemical action on mucus, cellular antioxidant support, and modulation of inflammatory pathways. Research notes that evidence quality varies and that long-term effects are not fully established.


Q: What is the risk of dependence or addiction with Mucomax?

Official product information, according to regulatory bodies, notes that the medicine is not addictive.


Q: Are there any foods or drinks that should be avoided when using Mucomax?

The administration instructions for the oral solution involve mixing it with a soft drink or juice to improve the taste. There are no specific common foods listed in the product labeling that must be avoided, though interactions with other substances like Activated Charcoal are documented.


Q: How does Mucomax's purpose differ from a preventative medicine?

The medicine acts as both a mucolytic agent and an acute antidote. Clinical studies have also investigated its use for the prevention of acute exacerbations in conditions such as Chronic Obstructive Pulmonary Disease (COPD). Therefore, its use has been studied in both acute treatment and preventative contexts.


Q: Are there any long-term side effects noted in official Mucomax documents?

The majority of available research evidence is concentrated on short-term follow-up periods. Long-term effects of the medicine are noted as not fully established for certain uses in the available studies, and side effects are typically classified by frequency rather than duration.


Q: Does Mucomax cause sun sensitivity?

The official documentation of possible side effects from regulatory authorities does not list sun sensitivity (photosensitivity) as a reported adverse reaction.


Q: How do scientists describe the absorption of Mucomax in the body?

Following oral use, the drug is rapidly absorbed but undergoes significant metabolism in the liver. This results in a low overall bioavailability (approximately 10%) of the orally administered form.


Q: Is the evidence for Mucomax use strong across all age groups?

Research evidence is not consistent across all age groups. For instance, the safety and effectiveness have not been established in older adults, and specific prohibitions on mucolytic use exist for children under 2 years old.

How should Mucomax be stored and disposed of?

How to Store and Dispose of Mucomax (Acetylcysteine)

Official regulatory guidelines define specific requirements for the storage, handling, and disposal of Mucomax, which vary by product form.

  • Storage Temperature: Unopened solutions are typically stored at 20 C to 25 C or below 30 C. The product must be kept in its original container, which must be tightly closed and protected from excess heat and moisture.

  • Stability After Opening: The undiluted opened vial for inhalation, if refrigerated at 2 C to 8 C, must be discarded after 96 hours. Diluted solutions prepared for administration must generally be used within one to three hours.

  • Handling: The solution is not compatible with certain metals or rubber; appropriate plastic or glass equipment must be used for administration. A color change to light purple does not significantly impair safety.

  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children and to store it locked up.

  • Disposal: Unused or expired Mucomax, including solution remaining after a session, must be disposed of in accordance with local, regional, and national regulations. Release to the environment should be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucomax found in:

A-Z Index: